Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMR-SPARE: Tocilizumab in New-Onset Polymyalgia Rheumatica
NCT03263715Phase 3Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2017
- Primary completion
- Jun 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Tocilizumab with Placebo (2 arms). Primary endpoint: Proportion of subjects in GC free remission at 16 weeks. Started Nov 2017; status: completed.
02
Drugs
tocilizumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT03263715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263715.